Mathematical modelling long-term effects of replacing prevnar7 with prevnar13 on invasive pneumococcal diseases in england and wales

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Choi, Yoon Hong ^a   Jit, Mark ^a,b   Flasche, Stefan ^a,c   Gay, Nigel ^d   Miller, Elizabeth ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d Fu Consulting   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; PREVNAR 7; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL TRANSMISSION; CHILD; COMPARTMENT MODEL; DRUG EFFICACY; HEALTH CARE POLICY; HUMAN; INFANT; INFECTION PREVENTION; MATHEMATICAL MODEL; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; SCHOOL CHILD; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TREND STUDY; UNITED KINGDOM; VACCINATION;

COST-BENEFIT ANALYSIS; ENGLAND; HUMANS; INCIDENCE; MODELS, IMMUNOLOGICAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TIME; VACCINATION; VACCINES, CONJUGATE; WALES;

EID: 84863752479     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039927     Document Type: Article

References (16)

1. Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, et al. (2010) Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC infectious diseases 10: 90 doi:10.1186/1471-2334-10-90.
2. Miller E, Andrews NJ, Waight PA, Slack MP, George RC, (2011) Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. The Lancet infectious diseases 3099: 1-9 doi:10.1016/S1473-3099(11)70090-1.
3. Weinberger DM, Malley R, Lipsitch M, (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 6736: 1-12 doi:10.1016/S0140-6736(10)62225-8.
4. Choi YH, Jit M, Gay N, Andrews N, Waight PA, et al. (2011) 7-Valent Pneumococcal Conjugate Vaccination in England and Wales: Is It Still Beneficial Despite High Levels of Serotype Replacement? PLoS ONE 6: e26190.
5. Hussain M, Melegaro A, Pebody RG, George R, Edmunds WJ, et al. (2005) A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiology and infection 133: 891-898 doi:10.1017/S0950268805004012.
6. Mossong J, Hens N, Jit M, Beutels P, Auranen K, et al. (2008) Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS medicine 5: e74 doi:10.1371/journal.pmed.0050074.
7. Flasche S, Slack M, Miller E, (2011) Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales. Eurosurveillance 16(20): pii = 19868.
8. Turner P, Hinds J, Turner C, Jankhot A, Gould K, et al. (2011) Improved detection of nasopharyngeal cocolonization by multiple pneumococcal serotypes by use of latex agglutination or molecular serotyping by microarray. Journal of clinical microbiology 49: 1784-1789 doi:10.1128/JCM.00157-11.
9. Rinta-Kokko H, Dagan R, Givon-Lavi N, Auranen K, (2009) Estimation of vaccine efficacy against acquisition of pneumococcal carriage. Vaccine 27: 3831-3837 doi:10.1016/j.vaccine.2009.04.009.
10. Colijn C, Cohen T, Fraser C, Hanage W, Goldstein E, et al. (2010) What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae? Journal of the Royal Society, Interface/the Royal Society 7: 905-919 doi:10.1098/rsif.2009.0400.
11. Flasche S, Van Hoek AJ, Sheasby E, Waight P, Andrews N, et al. (2011) Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS medicine 8: e1001017 doi:10.1371/journal.pmed.1001017.
12. Auranen K, Mehtala J, Tanskanen A, Kaltoft MS, (2010) Between-strain competition in acquisition and clearance of pneumococcal carriage-epidemiologic evidence from a longitudinal study of day-care children. Am J Epidemiol 171: 169-176 doi:10.1093/aje/kwp351.
13. Robberstad B, Frostad CR, Akselsen PE, Kværner KJ, Berstad AKH, (2011) Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine 29: 8564-8574 doi:10.1016/j.vaccine.2011.09.025.
14. Strutton DR, Farkouh RA, Earnshaw SR, Hwang S, Theidel U, et al. (2012) Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. The Journal of infection 64: 54-67 doi:10.1016/j.jinf.2011.10.015.
15. Boccalini S, Azzari C, Resti M, Valleriani C, Cortimiglia M, et al. (2011) Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy. Vaccine 29: 9521-9528 doi:10.1016/j.vaccine.2011.10.013.
16. De Wals P, Black S, Borrow R, Pearce D, (2009) Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model. Clinical therapeutics 31: 2152-2169 doi:10.1016/j.clinthera.2009.10.014.